Borm K, Slawik M, Seiler L, Flohr F, Petrick M, Honegger J, Reincke M
Division of Endocrinology, Department of Medicine 2, University Hospital of Freiburg, Germany.
Eur J Endocrinol. 2003 Dec;149(6):535-41. doi: 10.1530/eje.0.1490535.
The insulin tolerance test (ITT) is an established standardized test for the evaluation of the hypothalamic-pituitary-adrenal axis. While a peak cortisol value of >18 microg/dl is usually interpreted as a sufficient response to the ITT, the plasma ACTH response has not yet been standardized.
We evaluated retrospectively the peak plasma ACTH concentrations during 140 ITTs in 125 patients with suspected pituitary insufficiency and prospectively in 15 healthy subjects.
All healthy subjects had a peak cortisol concentration >/=18 microg/dl; 32 of 125 tests in the patients showed an insufficient cortisol response (peak cortisol concentration <18 microg/dl). The peak stimulated ACTH concentration in patients with secondary adrenal insufficiency (SAI) was 49.2+/-37.2 pg/ml (mean+/-s.d.) vs 130.9+/-89.3 pg/ml in patients without SAI, and 110.9+/-55.4 pg/ml in normal subjects (P<0.001). There was a weak, but significantly positive correlation between the peak ACTH and peak cortisol concentrations (rho=0.446, P<0.001), but there was also a very wide spread of the values. Defining a cut-off value for the peak plasma ACTH concentration with a sufficient sensitivity and specificity to identify patients with an impaired hypothalamic-pituitary-adrenal (HPA) axis was not possible. A peak plasma ACTH <20 pg/ml as a cut-off value had a sensitivity of 25% and a specificity of 98% for SAI. A cut-off value of a peak plasma ACTH <140 pg/ml had a sensitivity of 97% but a low specificity of 39%.
Although there is a significant positive correlation between the peak ACTH and the peak cortisol concentrations, we conclude that there is no additional benefit in determining the ACTH concentrations during an ITT. Because of the strong variations of the values, the peak ACTH concentration is a poor parameter for the evaluation of the HPA axis.
胰岛素耐量试验(ITT)是一种用于评估下丘脑 - 垂体 - 肾上腺轴的既定标准化试验。虽然皮质醇峰值>18μg/dl通常被解释为对ITT的充分反应,但血浆促肾上腺皮质激素(ACTH)反应尚未标准化。
我们回顾性评估了125例疑似垂体功能不全患者140次ITT期间的血浆ACTH峰值浓度,并前瞻性评估了15名健康受试者的情况。
所有健康受试者的皮质醇峰值浓度≥18μg/dl;患者的125次试验中有32次显示皮质醇反应不足(皮质醇峰值浓度<18μg/dl)。继发性肾上腺功能不全(SAI)患者的刺激后ACTH峰值浓度为49.2±37.2 pg/ml(平均值±标准差),无SAI患者为130.9±89.3 pg/ml,正常受试者为110.9±55.4 pg/ml(P<0.001)。ACTH峰值与皮质醇峰值浓度之间存在微弱但显著的正相关(rho = 0.446,P<0.001),但数值分布也非常分散。无法确定具有足够敏感性和特异性以识别下丘脑 - 垂体 - 肾上腺(HPA)轴受损患者的血浆ACTH峰值浓度临界值。血浆ACTH峰值<20 pg/ml作为临界值时,对SAI的敏感性为25%,特异性为98%。血浆ACTH峰值<140 pg/ml的临界值敏感性为97%,但特异性低至39%。
虽然ACTH峰值与皮质醇峰值浓度之间存在显著正相关,但我们得出结论,在ITT期间测定ACTH浓度并无额外益处。由于数值变化很大,ACTH峰值浓度是评估HPA轴的一个不良参数。